Found: 22
Select item for more details and to access through your institution.
Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29052-7
- By:
- Publication type:
- Article
Modulatory Effects of Modafinil on Neural Circuits Regulating Emotion and Cognition.
- Published in:
- Neuropsychopharmacology, 2010, v. 35, n. 10, p. 2101, doi. 10.1038/npp.2010.83
- By:
- Publication type:
- Article
Challenges and Opportunities for Clinical Trials in Patients With Glioma.
- Published in:
- 2023
- By:
- Publication type:
- Opinion
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 1, p. 76, doi. 10.1093/neuonc/noaa207
- By:
- Publication type:
- Article
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 1, p. 94, doi. 10.1093/neuonc/noz164
- By:
- Publication type:
- Article
Accelerated progression of IDH mutant glioma after first recurrence.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 5, p. 669, doi. 10.1093/neuonc/noz016
- By:
- Publication type:
- Article
NIMG-68. MRI CHANGES IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED AS PART OF A PHASE II TRIAL WITH BAVITUXIMAB, RADIATION, AND TEMOZOLOMIDE.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi191, doi. 10.1093/neuonc/noy148.792
- By:
- Publication type:
- Article
ACTR-33. TUMOR TISSUE PENETRATION AND PHARMACODYNAMICS OF ONC201 IN ADULT RECURRENT GLIOBLASTOMA PATIENTS.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi18, doi. 10.1093/neuonc/noy148.066
- By:
- Publication type:
- Article
EPID-11. PROGRESSION OF IDH MUTANT GLIOMA AFTER FIRST RECURRENCE: DEVELOPMENT OF A FEASIBLE CLINICAL TRIAL ENDPOINT IN THE RECURRENT SETTING.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi82, doi. 10.1093/neuonc/noy148.338
- By:
- Publication type:
- Article
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-03905-6
- By:
- Publication type:
- Article
Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of µ-opioid receptor mRNA and FosB/ΔFosB immunoreactivity.
- Published in:
- European Journal of Neuroscience, 2008, v. 27, n. 9, p. 2272, doi. 10.1111/j.1460-9568.2008.06176.x
- By:
- Publication type:
- Article
Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.
- Published in:
- Journal of Neuro-Oncology, 2021, v. 152, n. 3, p. 515, doi. 10.1007/s11060-021-03719-5
- By:
- Publication type:
- Article
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.
- Published in:
- Oncologist, 2022, v. 27, n. 7, p. 518, doi. 10.1093/oncolo/oyac069
- By:
- Publication type:
- Article
Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.
- Published in:
- Neuro-Oncology, 2024, v. 26, n. 6, p. 991, doi. 10.1093/neuonc/noae051
- By:
- Publication type:
- Article
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S165, doi. 10.1093/neuonc/noae021
- By:
- Publication type:
- Article
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S173, doi. 10.1093/neuonc/noae031
- By:
- Publication type:
- Article
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S89, doi. 10.1093/neuonc/noad245
- By:
- Publication type:
- Article
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
- Published in:
- Neuro-Oncology, 2023, v. 25, n. 12, p. 2239, doi. 10.1093/neuonc/noad118
- By:
- Publication type:
- Article
IDH-mutant glioma: A new IDH1 inhibitor moves forward.
- Published in:
- Neuro-Oncology, 2023, v. 25, n. 2, p. 337, doi. 10.1093/neuonc/noac275
- By:
- Publication type:
- Article
Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 12, p. 2180, doi. 10.1093/neuonc/noac126
- By:
- Publication type:
- Article
Enhancing demethylation-induced differentiation in IDH-mutant glioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 5, p. 724, doi. 10.1093/neuonc/noac056
- By:
- Publication type:
- Article